AI Article Synopsis
- Electroconvulsive therapy (ECT) is mainly used for mood disorders and schizophrenia, but there’s a lack of guidelines for its use in patients with brain tumors.
- A case study is presented where a patient with recurrent depressive disorder and a meningioma successfully received three courses of modified ECT without neurological issues.
- The report explores the connection between brain tumors and depression, highlighting the need for more insights into ECT administration in these complex cases.
Article Abstract
Electroconvulsive therapy (ECT) is primarily indicated for mood disorders and schizophrenia. Clinicians may encounter cases in which ECT is administered to patients with various kinds of complications. However, to our knowledge, no detailed medical guideline is available about the indications for ECT in psychiatric illness complicated with a concomitant brain tumor, which is one of the most likely physical complications that can directly affect ECT. We report a case in which 3 courses of modified ECT (m-ECT) were successfully administered without any neurological deterioration to a patient, who was frequently hospitalized for recurrent depressive disorder with stupor. We did not undertake any additional measures for reducing adverse events derived from the meningioma during m-ECT. In this report, we discuss the relation between brain tumor and depression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Early-onset Alzheimer's disease (EOAD) associated with amyloid precursor protein (APP) duplications or presenilin (PSEN) variants increases risk of seizures. Targeting epileptiform activity with antiseizure medicine (ASM) administration to AD patients may beneficially attenuate cognitive decline (Vossel et al, JAMA Neurology 2021). However, whether mechanistically distinct ASMs differentially suppress seizures in discrete EOAD models is understudied (Lehmann et al, Neurochem Res 2021).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
RWJ Barnabas Health, West Orange, NJ, USA.
Background: Effect and Safety of Electroconvulsive Therapy plus Usual Care for the Acute Management of Severe Agitation in Dementia (ECT-AD) is a multi-site NIA-funded FDA-regulated pioneering clinical trial to investigate the effectiveness of electroconvulsive therapy (ECT) in treating severe and treatment-refractory agitation and aggression among individuals with advanced dementia, a condition that has a profound negative impact on patient quality of life and caregiver burden. Here we present baseline demographics of the patient population in this ongoing trial.
Method: To date we have enrolled 18 participants, with a mean age of 74.
Bilateral hypothalamotomy plus dominant amygdalotomy with Gamma Knife radiosurgery. A non-invasive alternative when everything has failed in the management of aggressive behavior disorder.
Surg Neurol Int
December 2024
Department of Neurosurgery, Fundación Clínica Shaio, Bogotá, Colombia.
Background: Impulsive aggression is the core symptom of intermittent explosive disorder, which can be a feature of several psychiatric disorders. There is a subset of individuals who do not respond adequately to medical treatment; they are treatment refractory. The objective of this report is to describe a case of a patient with a background of schizophrenia and concomitant refractory aggressiveness disorder, treated with two-stage bilateral hypothalamotomy and unilateral amygdalotomy with Gamma Knife radiosurgery (GKR).
View Article and Find Full Text PDFExploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review.
Medicina (Kaunas)
December 2024
Non-Invasive Neuromodulation Consortium for Mental Disorders, Society of Psychophysiology, Taipei 114, Taiwan.
Cognitive deficits are emerging as critical targets for managing schizophrenia and enhancing clinical and functional outcomes. These deficits are pervasive among individuals with schizophrenia, affecting various cognitive domains. Traditional pharmacotherapy and cognitive behavioral therapy (CBT) have limitations in effectively addressing cognitive impairments in this population.
View Article and Find Full Text PDFNeuromodulation Strategies in Lifelong Bipolar Disorder: A Narrative Review.
Behav Sci (Basel)
December 2024
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazza Aldo Moro, 100165 Rome, Italy.
Bipolar disorder is a debilitating psychiatric condition characterized by recurrent episodes of mania and depression, affecting millions worldwide. While pharmacotherapy remains the cornerstone of treatment, a significant proportion of patients exhibit inadequate response or intolerable side effects to conventional medications. In recent years, neuromodulation techniques have emerged as promising adjunctive or alternative treatments for bipolar disorder.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!